Unnamed: 0
int64 0
1.41M
| headline
stringlengths 3
513
| url
stringlengths 33
162
| publisher
stringlengths 3
46
| date
timestamp[s] | stock
stringlengths 1
5
|
|---|---|---|---|---|---|
1,412,321 | Option Alert: Zoetis Jan 27th 53.5 Calls Sweep: 1425 @ ASK $1.20: 1425 traded vs 68 OI: Earnings 2/16 Before Open $53.89 Ref | https://www.benzinga.com/markets/options/17/01/8927910/option-alert-zoetis-jan-27th-53-5-calls-sweep-1425-ask-1-20-1425-trade | Charles Gross | 2017-01-20T00:00:00 | ZTS |
1,412,322 | Wall Street's M&A Chatter From January 18 | https://www.benzinga.com/news/17/01/8921323/wall-streets-m-a-chatter-from-january-18 | Charles Gross | 2017-01-19T00:00:00 | ZTS |
1,412,323 | Handelsblatt Says Boehringer, 'Setting its sights on Zoetis' Due To Attractive Nature Of Animal Health Sector | https://www.benzinga.com/news/17/01/8917474/handelsblatt-says-boehringer-setting-its-sights-on-zoetis-due-to-attractive-natur | Paul Quintaro | 2017-01-18T00:00:00 | ZTS |
1,412,324 | Zoetis Spikes to High of $54.01 on Volume | https://www.benzinga.com/news/17/01/8917468/zoetis-spikes-to-high-of-54-01-on-volume | Charles Gross | 2017-01-18T00:00:00 | ZTS |
1,412,325 | JP Morgan Healtchare Conf. Continues Today; Presenters Include Novocure, Zoetis, Oxford Immunotec, Enanta, Irhythm Tech, Walgreen's, & Mylan | https://www.benzinga.com/news/events/17/01/8894109/jp-morgan-healtchare-conf-continues-today-presenters-include-novocure-zoet | Hal Lindon | 2017-01-11T00:00:00 | ZTS |
1,412,326 | Zoetis Receives USDA License For CYTOPOINT | https://www.benzinga.com/news/16/12/8833064/zoetis-receives-usda-license-for-cytopoint | Hal Lindon | 2016-12-21T00:00:00 | ZTS |
1,412,327 | Deutsche Bank Initiates Coverage On Zoetis at Buy, Announces $62.00 Target | https://www.benzinga.com/news/16/12/8824888/deutsche-bank-initiates-coverage-on-zoetis-at-buy-announces-62-00-target | Paul Quintaro | 2016-12-20T00:00:00 | ZTS |
1,412,328 | Jefferies' 2017 Global Pharma Outlook | https://www.benzinga.com/analyst-ratings/analyst-color/16/12/8820515/jefferies-2017-global-pharma-outlook | Jim Swanson | 2016-12-19T00:00:00 | ZTS |
1,412,329 | 7 Biggest Price Target Changes For Thursday | https://www.benzinga.com/analyst-ratings/price-target/16/12/8810241/7-biggest-price-target-changes-for-thursday | Lisa Levin | 2016-12-15T00:00:00 | ZTS |
1,412,330 | Benzinga's Top Upgrades, Downgrades For December 15, 2016 | https://www.benzinga.com/analyst-ratings/upgrades/16/12/8810129/benzingas-top-upgrades-downgrades-for-december-15-2016 | Lisa Levin | 2016-12-15T00:00:00 | ZTS |
1,412,331 | The Market In 5 Minutes: Interest Rate Hike Finally Arrives | https://www.benzinga.com/news/16/12/8809262/the-market-in-5-minutes-interest-rate-hike-finally-arrives | Benzinga News Desk | 2016-12-15T00:00:00 | ZTS |
1,412,332 | PiperJaffray Reinstates Overweight on Zoetis, Announces $61.00 Target | https://www.benzinga.com/news/16/12/8809479/piperjaffray-reinstates-overweight-on-zoetis-announces-61-00-target | Paul Quintaro | 2016-12-15T00:00:00 | ZTS |
1,412,333 | Cowen & Co. Upgrades Zoetis to Outperform, Raises Target to $60.00 | https://www.benzinga.com/news/16/12/8808847/cowen-co-upgrades-zoetis-to-outperform-raises-target-to-60-00 | Paul Quintaro | 2016-12-15T00:00:00 | ZTS |
1,412,334 | Bill Ackman's Pershing Square Issues Q3 Shareholder Letter | https://www.benzinga.com/news/16/12/8783218/bill-ackmans-pershing-square-issues-q3-shareholder-letter | Paul Quintaro | 2016-12-07T00:00:00 | ZTS |
1,412,335 | Zoetis Reports $1.5 Billion Share Repurchase Program | https://www.benzinga.com/news/16/12/8777825/zoetis-reports-1-5-billion-share-repurchase-program | Paul Quintaro | 2016-12-06T00:00:00 | ZTS |
1,412,336 | 13F from Bill Ackman's Pershing Square Shows Reduced Stake in Zoetis from ~21.17M Shares to ~2.71M Shares | https://www.benzinga.com/news/16/11/8697805/13f-from-bill-ackmans-pershing-square-shows-reduced-stake-in-zoetis-from-21-17m-s | Paul Quintaro | 2016-11-14T00:00:00 | ZTS |
1,412,337 | Watch These 5 Huge Put Purchases In Friday Trade | https://www.benzinga.com/markets/options/16/11/8685253/watch-these-5-huge-put-purchases-in-friday-trade | Lisa Levin | 2016-11-11T00:00:00 | ZTS |
1,412,338 | Pershing Square No Longer Holds A Position In Zoetis | https://www.benzinga.com/general/biotech/16/11/8681222/pershing-square-no-longer-holds-a-position-in-zoetis | Jayson Derrick | 2016-11-10T00:00:00 | ZTS |
1,412,339 | Pershing Square Confirms To Benzinga That Bill Ackman Announced This Morning That He Sold His Stake In Zoetis On Pershing Square Holdings Quarterly Investor Call | https://www.benzinga.com/news/16/11/8680944/pershing-square-confirms-to-benzinga-that-bill-ackman-announced-this-morning-that | Paul Quintaro | 2016-11-10T00:00:00 | ZTS |
1,412,340 | Option Alert: ZTS Fri 11/11 50.5 Puts (Wkly) Sweep: 500 @ ASK $0.40: 500 traded vs 304 OI: Earnings 2/16 Before Open (est) $50.71 Ref | https://www.benzinga.com/markets/options/16/11/8680721/option-alert-zts-fri-1111-50-5-puts-wkly-sweep-500-ask-0-40-500-traded | Charles Gross | 2016-11-10T00:00:00 | ZTS |
1,412,341 | Zoetis Shares Dipping Lower as Hearing Bill Ackman May Have Liquidated Position | https://www.benzinga.com/news/16/11/8680719/zoetis-shares-dipping-lower-as-hearing-bill-ackman-may-have-liquidated-position | Paul Quintaro | 2016-11-10T00:00:00 | ZTS |
1,412,342 | Zoetis Raises FY17 Adj. EPS Outlook from $2.24-$2.38 to $2.28-$2.38 vs $2.32 Est. | https://www.benzinga.com/news/16/11/8636239/zoetis-raises-fy17-adj-eps-outlook-from-2-24-2-38-to-2-28-2-38-vs-2-32-est | Paul Quintaro | 2016-11-02T00:00:00 | ZTS |
1,412,343 | UPDATE: Zoetis Raises FY16 Adj. EPS Outlook from $1.86-$1.93 to $1.91-$1.96 vs $1.91 Est., Sales $4.85B-$4.9B vs $4.88B Est. | https://www.benzinga.com/news/16/11/8636232/update-zoetis-raises-fy16-adj-eps-outlook-from-1-86-1-93-to-1-91-1-96-vs-1-91-est | Paul Quintaro | 2016-11-02T00:00:00 | ZTS |
1,412,344 | Zoetis Raises FY16, FY17 Outlooks | https://www.benzinga.com/news/16/11/8636222/zoetis-raises-fy16-fy17-outlooks | Paul Quintaro | 2016-11-02T00:00:00 | ZTS |
1,412,345 | Zoetis Reports Q3 Adj. EPS $0.52 vs $0.47 Est., Sales $1.2B vs $1.22B Est. | https://www.benzinga.com/news/earnings/16/11/8636214/zoetis-reports-q3-adj-eps-0-52-vs-0-47-est-sales-1-2b-vs-1-22b-est | Paul Quintaro | 2016-11-02T00:00:00 | ZTS |
1,412,346 | 10 Stocks That Plummeted The Past Three Days On Increasing Volume | https://www.benzinga.com/general/movers-shakers/16/11/8636062/10-stocks-that-plummeted-the-past-three-days-on-increasing-volu | Lisa Levin | 2016-11-02T00:00:00 | ZTS |
1,412,347 | 10 Notable Stocks Trading Ex-Dividend Tuesday, November 1 | https://www.benzinga.com/news/dividends/16/10/8624783/10-notable-stocks-trading-ex-dividend-tuesday-november-1 | Lisa Levin | 2016-10-31T00:00:00 | ZTS |
1,412,348 | VCA Shares Down 6% Following Q3 Miss; Other Animal Health Stocks Moving in Sympathy: Zoetis Down ~1.8%, Aratana Therapeutics Down 0.7%, Parnell Pharma Down 2%, Phibro Animal Health Up 0.3% | https://www.benzinga.com/news/earnings/16/10/8603525/vca-shares-down-6-following-q3-miss-other-animal-health-stocks-moving-in | Paul Quintaro | 2016-10-26T00:00:00 | ZTS |
1,412,349 | Benzinga's Top Initiations | https://www.benzinga.com/analyst-ratings/initiation/16/09/8509682/benzingas-top-initiations | Monica Gerson | 2016-09-29T00:00:00 | ZTS |
1,412,350 | Bank of America Initiates Coverage on Zoetis at Buy | https://www.benzinga.com/news/16/09/8509341/bank-of-america-initiates-coverage-on-zoetis-at-buy | Paul Quintaro | 2016-09-29T00:00:00 | ZTS |
1,412,351 | Zoetis Capitalizing On Lack Of Competition In Generic Animal Drug Competition | https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8440800/zoetis-capitalizing-on-lack-of-competition-in-generic-an | Jim Swanson | 2016-09-09T00:00:00 | ZTS |
1,412,352 | Credit Suisse Focus List Additions: PGR, SLCA, ZTS | https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8429623/credit-suisse-focus-list-additions-pgr-slca-zts | Paul Quintaro | 2016-09-07T00:00:00 | ZTS |
1,412,353 | Barron's Picks And Pans: Good News For Barnes & Noble And Zoetis, But 'Beware The Bear' | https://www.benzinga.com/trading-ideas/long-ideas/16/09/8422395/barrons-picks-and-pans-good-news-for-barnes-noble-and-zoetis- | Nelson Hem | 2016-09-04T00:00:00 | ZTS |
1,412,354 | A Cascade Of Corporate Exec Hires This Week | https://www.benzinga.com/news/16/08/8391113/a-cascade-of-corporate-exec-hires-this-week | Jayson Derrick | 2016-08-25T00:00:00 | ZTS |
1,412,355 | Zoetis Names Glenn David as CFO | https://www.benzinga.com/news/16/08/8376426/zoetis-names-glenn-david-as-cfo | Charles Gross | 2016-08-22T00:00:00 | ZTS |
1,412,356 | The Least Popular Stocks This 13F Season | https://www.benzinga.com/news/16/08/8358063/the-least-popular-stocks-this-13f-season | R. Chandrasekaran | 2016-08-16T00:00:00 | ZTS |
1,412,357 | 13F from Ackman's Pershing Square Shows Reduced Stake in Zoetis from ~41.8M Shares to ~21.17M Shares | https://www.benzinga.com/news/16/08/8354215/13f-from-ackmans-pershing-square-shows-reduced-stake-in-zoetis-from-41-8m-shares- | Paul Quintaro | 2016-08-15T00:00:00 | ZTS |
1,412,358 | Zoetis Reports Deal to Buy Scandinavian Micro Biodevices for $80M | https://www.benzinga.com/news/16/08/8318312/zoetis-reports-deal-to-buy-scandinavian-micro-biodevices-for-80m | Paul Quintaro | 2016-08-08T00:00:00 | ZTS |
1,412,359 | 20 Biggest Mid-Day Gainers For Wednesday | https://www.benzinga.com/news/16/08/8299536/20-biggest-mid-day-gainers-for-wednesday | Lisa Levin | 2016-08-03T00:00:00 | ZTS |
1,412,360 | 20 Stocks Moving In Wednesday's Pre-Market Session | https://www.benzinga.com/news/16/08/8297780/20-stocks-moving-in-wednesdays-pre-market-session | Monica Gerson | 2016-08-03T00:00:00 | ZTS |
1,412,361 | UPDATE: Zoetis Raises FY16 Sales Outlook from $1.83-$1.90 to $1.86-$1.93 vs $1.87 Est., Sales from $4.775B-$4.875B to $4.8B-$4.9B vs $4.85B Est. | https://www.benzinga.com/news/16/08/8297167/update-zoetis-raises-fy16-sales-outlook-from-1-83-1-90-to-1-86-1-93-vs-1-87-est-s | Paul Quintaro | 2016-08-03T00:00:00 | ZTS |
1,412,362 | Zoetis Raises FY Outlook | https://www.benzinga.com/news/16/08/8297159/zoetis-raises-fy-outlook | Paul Quintaro | 2016-08-03T00:00:00 | ZTS |
1,412,363 | Zoetis Reports Q2 Adj. EPS $0.49 vs $0.44 Est., Sales $1.2B vs $1.17B Est. | https://www.benzinga.com/news/earnings/16/08/8297155/zoetis-reports-q2-adj-eps-0-49-vs-0-44-est-sales-1-2b-vs-1-17b-est | Paul Quintaro | 2016-08-03T00:00:00 | ZTS |
1,412,364 | 5 Pharmaceutical Price Target Raises From Jefferies | https://www.benzinga.com/analyst-ratings/analyst-color/16/06/8110291/5-pharmaceutical-price-target-raises-from-jefferies | Andrew Efimoff | 2016-06-14T00:00:00 | ZTS |
1,412,365 | Citi Downgrades Zoetis, Cites Valuation | https://www.benzinga.com/analyst-ratings/analyst-color/16/06/8097607/citi-downgrades-zoetis-cites-valuation | Jim Swanson | 2016-06-10T00:00:00 | ZTS |
1,412,366 | 5 Largest Price Target Changes For Friday | https://www.benzinga.com/analyst-ratings/price-target/16/06/8097780/5-largest-price-target-changes-for-friday | Monica Gerson | 2016-06-10T00:00:00 | ZTS |
1,412,367 | The Market In 5 Minutes: Gotta Get Down On Friday | https://www.benzinga.com/news/16/06/8097430/the-market-in-5-minutes-gotta-get-down-on-friday | Benzinga News Desk | 2016-06-10T00:00:00 | ZTS |
1,412,368 | Citigroup Downgrades Zoetis to Neutral, Raises PT to $50.00 | https://www.benzinga.com/news/16/06/8097014/citigroup-downgrades-zoetis-to-neutral-raises-pt-to-50-00 | Eddie Staley | 2016-06-10T00:00:00 | ZTS |
1,412,369 | Stifel Initiates Coverage On Zoetis, Sets $58 Target | https://www.benzinga.com/analyst-ratings/analyst-color/16/06/8056196/stifel-initiates-coverage-on-zoetis-sets-58-target | Dhiraj Surapaneni | 2016-06-01T00:00:00 | ZTS |
1,412,370 | Benzinga's Top Initiations | https://www.benzinga.com/analyst-ratings/initiation/16/06/8055343/benzingas-top-initiations | Monica Gerson | 2016-06-01T00:00:00 | ZTS |
1,412,371 | Stifel Nicolaus Initiates Coverage on Zoetis at Buy, Announces $58.00 PT | https://www.benzinga.com/news/16/06/8053724/stifel-nicolaus-initiates-coverage-on-zoetis-at-buy-announces-58-00-pt | Eddie Staley | 2016-06-01T00:00:00 | ZTS |
1,412,372 | Jefferies Updates Price Targets In Global Pharma, Sees 'Rich Catalyst Environment' Ahead | https://www.benzinga.com/analyst-ratings/analyst-color/16/05/7966287/jefferies-updates-price-targets-in-global-pharma-sees-ri | Wayne Duggan | 2016-05-11T00:00:00 | ZTS |
1,412,373 | Amended 13D Filing from Bill Ackman's Pershing Square Shows Reduced Stake in Zoetis to 5% | https://www.benzinga.com/news/16/05/7962796/amended-13d-filing-from-bill-ackmans-pershing-square-shows-reduced-stake-in-zoeti | Paul Quintaro | 2016-05-10T00:00:00 | ZTS |
1,412,374 | Zoetis Shares Fall After-Hours on NY Times Report that Bill Ackman's Pershing Square was Selling 16.85M Shares | https://www.benzinga.com/news/16/05/7955423/zoetis-shares-fall-after-hours-on-ny-times-report-that-bill-ackmans-pershing-squa | Charles Gross | 2016-05-09T00:00:00 | ZTS |
1,412,375 | Goldman Downgrades Zoetis, Sees Limited Upside | https://www.benzinga.com/analyst-ratings/analyst-color/16/05/7943897/goldman-downgrades-zoetis-sees-limited-upside | Jim Swanson | 2016-05-06T00:00:00 | ZTS |
1,412,376 | Goldman Sachs Downgrades Zoetis to Sell, Raises PT to $48.00 | https://www.benzinga.com/news/16/05/7942316/goldman-sachs-downgrades-zoetis-to-sell-raises-pt-to-48-00 | Eddie Staley | 2016-05-06T00:00:00 | ZTS |
1,412,377 | Zoetis Sees FY16 Sales $5.075B-$5.275B vs $5.06B Est., Adj. EPS $2.24-$2.38 vs $2.26 Est. | https://www.benzinga.com/news/16/05/7927206/zoetis-sees-fy16-sales-5-075b-5-275b-vs-5-06b-est-adj-eps-2-24-2-38-vs-2-26-est | Paul Quintaro | 2016-05-04T00:00:00 | ZTS |
1,412,378 | Zoetis Raises FY16 Sales Outlook to $4.775B-$4.875B vs $4.75B Est., Adj. EPS $1.83-$1.90 vs $1.79 Est. | https://www.benzinga.com/news/16/05/7927204/zoetis-raises-fy16-sales-outlook-to-4-775b-4-875b-vs-4-75b-est-adj-eps-1-83-1-90- | Paul Quintaro | 2016-05-04T00:00:00 | ZTS |
1,412,379 | Zoetis Reports Q1 Adj. EPS $0.48 vs $0.41 Est., Sales $1.2B vs $1.1B Est. | https://www.benzinga.com/news/earnings/16/05/7927199/zoetis-reports-q1-adj-eps-0-48-vs-0-41-est-sales-1-2b-vs-1-1b-est | Paul Quintaro | 2016-05-04T00:00:00 | ZTS |
1,412,380 | Earnings Scheduled For May 4, 2016 | https://www.benzinga.com/news/earnings/16/05/7926530/earnings-scheduled-for-may-4-2016 | Monica Gerson | 2016-05-04T00:00:00 | ZTS |
1,412,381 | Pershing Square Says It's 'Pleased' With Zoetis' Progress, Discloses Unchanged 8.4% Stake | https://www.benzinga.com/news/16/04/7878232/pershing-square-says-its-pleased-with-zoetis-progress-discloses-unchanged-8-4-sta | Jayson Derrick | 2016-04-25T00:00:00 | ZTS |
1,412,382 | Zoetis Announces Pershing Square Capital Management would Not be Exercising its Option to have Mr. William Doyle Serve on Company's Board of Directors through 2017 Annual Shareholders Meeting | https://www.benzinga.com/news/16/04/7876787/zoetis-announces-pershing-square-capital-management-would-not-be-exercising-its-o | Charles Gross | 2016-04-25T00:00:00 | ZTS |
1,412,383 | Lachapelle: If Bayer Expands In Animal Healthcare, Zoetis Is Obvious Choice | https://www.benzinga.com/general/biotech/16/04/7846243/lachapelle-if-bayer-expands-in-animal-healthcare-zoetis-is-obvious-cho | Manikandan Raman | 2016-04-15T00:00:00 | ZTS |
1,412,384 | Option Alert: ZTS Jan17 35.0 Puts: 42000 @ Above Ask! $2.30: 84k traded vs 88k OI: Earnings 5/3 $42.16 Ref | https://www.benzinga.com/markets/options/16/03/7744703/option-alert-zts-jan17-35-0-puts-42000-above-ask-2-30-84k-traded-vs-88 | Charles Gross | 2016-03-22T00:00:00 | ZTS |
1,412,385 | Zoetis Receives FDA Approval for SimparicaTM (sarolaner) Chewables | https://www.benzinga.com/news/16/02/6677540/zoetis-receives-fda-approval-for-simparicatm-sarolaner-chewables | Paul Quintaro | 2016-02-25T00:00:00 | ZTS |
1,412,386 | BMO Capital Positive On Zoetis, Says Current Price Is Good Entry For Fundamental Players, Expects Co To Hit Or Exceed Upper Bound Guidance In 2016 & 2017 | https://www.benzinga.com/analyst-ratings/analyst-color/16/02/6347185/bmo-capital-positive-on-zoetis-says-current-price-is-goo | Paul Quintaro | 2016-02-17T00:00:00 | ZTS |
1,412,387 | 13F from JANA Shows Liquidated Position in Zoetis | https://www.benzinga.com/news/16/02/6295981/13f-from-jana-shows-liquidated-position-in-zoetis | Paul Quintaro | 2016-02-16T00:00:00 | ZTS |
1,412,388 | Zoetis Sees Full Year 2017 Revenue Guidance to $4.950 - $5.150 Billion and Reaffirms Adjusted Diluted EPS of $2.18 - $2.32 | https://www.benzinga.com/news/16/02/6292784/zoetis-sees-full-year-2017-revenue-guidance-to-4-950-5-150-billion-and-reaffirms- | Hal Lindon | 2016-02-16T00:00:00 | ZTS |
1,412,389 | Zoetis Sees Full Year 2016 Revenue Guidance to $4.650 - $4.775 vs. Est. $4.82B Billion and Reaffirms Adjusted Diluted EPS of $1.71 - $1.81 vs. Est. $1.81 | https://www.benzinga.com/news/16/02/6292694/zoetis-sees-full-year-2016-revenue-guidance-to-4-650-4-775-vs-est-4-74b-billion-a | Hal Lindon | 2016-02-16T00:00:00 | ZTS |
1,412,390 | Zoetis Reports Q4 EPS $0.43 vs. Est. $0.39, Rev. $1.3B vs. Est. $1.25B | https://www.benzinga.com/news/earnings/16/02/6292661/zoetis-reports-q4-eps-0-43-vs-est-0-39-rev-1-3b-vs-est-1-25b | Hal Lindon | 2016-02-16T00:00:00 | ZTS |
1,412,391 | Earnings Scheduled For February 16, 2016 | https://www.benzinga.com/news/earnings/16/02/6286272/earnings-scheduled-for-february-16-2016 | Monica Gerson | 2016-02-16T00:00:00 | ZTS |
1,412,392 | Credit Suisse Initiates Coverage on Zoetis at Outperform, Announces $58.00 PT | https://www.benzinga.com/news/16/02/6210303/credit-suisse-initiates-coverage-on-zoetis-at-outperform-announces-58-00-pt | Eddie Staley | 2016-02-03T00:00:00 | ZTS |
1,412,393 | Zoetis to Sell 55% Stake in Manufacturing Site for $13M | https://www.benzinga.com/news/16/01/6141977/zoetis-to-sell-55-stake-in-manufacturing-site-for-13m | Paul Quintaro | 2016-01-14T00:00:00 | ZTS |
1,412,394 | UPDATE: Zoetis Cuts FY16 Adj. EPS Outlook by $0.13 | https://www.benzinga.com/news/16/01/6134985/update-zoetis-cuts-fy16-adj-eps-outlook-by-0-13 | Paul Quintaro | 2016-01-12T00:00:00 | ZTS |
1,412,395 | Zoetis Disappointed with EC News Related to Belgium's Tax Rulings, Implications for Co.; Sees Effective Tax Rate Increased in '16 | https://www.benzinga.com/news/16/01/6134965/zoetis-disappointed-with-ec-news-related-to-belgiums-tax-rulings-implications-for | Paul Quintaro | 2016-01-12T00:00:00 | ZTS |
1,412,396 | Zoetis To Sell Manufacturing Site in India for $29M | https://www.benzinga.com/news/16/01/6109670/zoetis-to-sell-manufacturing-site-in-india-for-29m | Paul Quintaro | 2016-01-05T00:00:00 | ZTS |
1,412,397 | Next Year Could Be Interesting For Spin-Off ETFs | https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6076841/next-year-could-be-interesting-for-spin-off-etfs | ETF Professor | 2015-12-29T00:00:00 | ZTS |
1,412,398 | Zoetis Is The Only Publicly-Traded Pure-Play Animal Health, Vaccine Company | https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6075674/zoetis-is-the-only-publicly-traded-pure-play-animal-heal | Jim Swanson | 2015-12-28T00:00:00 | ZTS |
1,412,399 | Zoetis Volume Spike | https://www.benzinga.com/news/15/12/6073299/zoetis-volume-spike | Charles Gross | 2015-12-24T00:00:00 | ZTS |
1,412,400 | Zoetis To Divest 2 Manufacturing Sites To Huvepharma, Zoetis Will Receive $40M Cash And Additional Considerations; Expects Transaction To Complete Q1 2016 | https://www.benzinga.com/news/15/12/6067735/zoetis-to-divest-2-manufacturing-sites-to-huvepharma-zoetis-will-receive-40m-cash | Hal Lindon | 2015-12-22T00:00:00 | ZTS |
1,412,401 | Benzinga's Weekend M&A Chatter | https://www.benzinga.com/news/15/12/6063565/benzingas-weekend-m-a-chatter | Charles Gross | 2015-12-20T00:00:00 | ZTS |
1,412,402 | Reuters Reports Bayer Could be Viewing Zoetis as Potential Takeover Target | https://www.benzinga.com/news/15/12/6061007/reuters-reports-bayer-could-be-viewing-zoetis-as-potential-takeover-target | Charles Gross | 2015-12-18T00:00:00 | ZTS |
1,412,403 | Zoetis Increases Qtr. Dividend From $0.0825 To $0.095/Share | https://www.benzinga.com/news/15/12/6054698/zoetis-increases-qtr-dividend-from-0-0825-to-0-095share | Hal Lindon | 2015-12-16T00:00:00 | ZTS |
1,412,404 | Major Pharma Group Outlook In 2016: Fundamentals To Outweigh Political Headwinds | https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6041783/major-pharma-group-outlook-in-2016-fundamentals-to-outwe | Jennifer Lynn | 2015-12-12T00:00:00 | ZTS |
1,412,405 | Dan Nathan Sees Unusual Options Activity In Zoetis | https://www.benzinga.com/media/cnbc/15/12/6010466/dan-nathan-sees-unusual-options-activity-in-zoetis | Craig Jones | 2015-12-01T00:00:00 | ZTS |
1,412,406 | Pfizer Delaying Decision to Split -NY Times Deal Book | https://www.benzinga.com/news/15/11/5999116/pfizer-delaying-decision-to-split-ny-times-deal-book | Charles Gross | 2015-11-24T00:00:00 | ZTS |
1,412,407 | JANA Shows New 3.89M Share Stake in Zoetis | https://www.benzinga.com/news/15/11/5980786/jana-shows-new-3-89m-share-stake-in-zoetis | Paul Quintaro | 2015-11-16T00:00:00 | ZTS |
1,412,408 | Zoetis Sees FY17 Adj. EPS $2.24-$2.38, Sales $5.025B-$5.225B | https://www.benzinga.com/news/15/11/5957084/zoetis-sees-fy17-adj-eps-2-24-2-38-sales-5-025b-5-225b | Paul Quintaro | 2015-11-03T00:00:00 | ZTS |
1,412,409 | Zoetis Sees FY16 SAdj. EPS $1.84-$1.94 vs $1.90 Est., Sales $4.75B-$4.875B vs $4.78B Est. | https://www.benzinga.com/news/15/11/5957082/zoetis-sees-fy16-sadj-eps-1-84-1-94-vs-1-90-est-sales-4-75b-4-875b-vs-4-78b-est | Paul Quintaro | 2015-11-03T00:00:00 | ZTS |
1,412,410 | Zoetis Updates FY15 Outlook: Adj. EPS $1.70-$1.74 vs $1.66 Est., Sales $4.7B-$4.75B vs $4.76B Est. | https://www.benzinga.com/news/15/11/5957067/zoetis-updates-fy15-outlook-adj-eps-1-70-1-74-vs-1-66-est-sales-4-7b-4-75b-vs-4-7 | Paul Quintaro | 2015-11-03T00:00:00 | ZTS |
1,412,411 | Zoetis Reports Q3 Adj. EPS $0.50 vs $0.40 Est., Sales $1.2B vs $1.18B Est. | https://www.benzinga.com/news/earnings/15/11/5957036/zoetis-reports-q3-adj-eps-0-50-vs-0-40-est-sales-1-2b-vs-1-18b-est | Paul Quintaro | 2015-11-03T00:00:00 | ZTS |
1,412,412 | Earnings Scheduled For November 3, 2015 | https://www.benzinga.com/news/earnings/15/11/5956707/earnings-scheduled-for-november-3-2015 | Monica Gerson | 2015-11-03T00:00:00 | ZTS |
1,412,413 | Permira Funds To Sell PHARMAQ To Zoetis For $765M | https://www.benzinga.com/news/15/11/5956344/permira-funds-to-sell-pharmaq-to-zoetis-for-765m | Hal Lindon | 2015-11-02T00:00:00 | ZTS |
1,412,414 | Zoetis Announces Will Purchase PHARMAQ for $765M | https://www.benzinga.com/news/15/11/5956318/zoetis-announces-will-purchase-pharmaq-for-765m | Paul Quintaro | 2015-11-02T00:00:00 | ZTS |
1,412,415 | Option Alert: $ZTS Nov $36 Put; 6500 Contracts @$0.45; Now $41.09 | https://www.benzinga.com/markets/options/15/10/5933242/option-alert-zts-nov-36-put-6500-contracts-0-45 | Charles Gross | 2015-10-21T00:00:00 | ZTS |
1,412,416 | Shares Of Zoetis Climbing Over Past 25 Minutes, Now Trading At $41.02/Share | https://www.benzinga.com/movers/15/10/5933214/shares-of-zoetis-climbing-over-past-25-minutes-now-trading-at-41-02share | Hal Lindon | 2015-10-21T00:00:00 | ZTS |
1,412,417 | For Zoetis, It's All About Margins And M&A | https://www.benzinga.com/analyst-ratings/analyst-color/15/09/5869187/for-zoetis-its-all-about-margins-and-m-a | Rahul Kaundal | 2015-09-28T00:00:00 | ZTS |
1,412,418 | UPDATE: Zoetis Shares Spike ~$1.50 Over Last Few Mins, Stock Now Up 2.9% for Session | https://www.benzinga.com/movers/15/09/5846918/update-zoetis-shares-spike-1-50-over-last-few-mins-stock-now-up-2-9-for-session | Paul Quintaro | 2015-09-17T00:00:00 | ZTS |
1,412,419 | Zoetis to Participate at 2015 Morgan Stanley Global Healthcare Conference on Friday, September 18, in New York | https://www.benzinga.com/news/15/09/5846905/zoetis-to-participate-at-2015-morgan-stanley-global-healthcare-conference-on-frid | Charles Gross | 2015-09-17T00:00:00 | ZTS |
1,412,420 | Option Alert: $ZTS Oct $46 Call; 1000 Contracts @Ask @$1.30; Now $45.04 | https://www.benzinga.com/markets/options/15/09/5846893/option-alert-zts-oct-46-call-1000-contracts-ask-1-30-now-45-04 | Charles Gross | 2015-09-17T00:00:00 | ZTS |